Comments From Dendreon's Conference Call (May 10, 2007)

by Jon C. Ogg
24/7 Wall St.



Dendreon (DNDN) hosted a painful conference call today, and despite management answering most questions you could hear some frustration and disappointment out of management. The FDA has requested additional data but not specified what form of data. The impact study is double blind and placebo controlled Phase III study under a binding FDA agreement. This will serve as the basis and they will complete and interim analysis next year and a final analysis in 2010.

The company is maintaining that they are committed to this process. As far as earnings for the quarter, but earnings are irrelevant because revenues were a whopping $80,000.00. It had $88+ million cash and equivalents at the end of the quarter and they think the cash is adequate to get them through to interim analysis in 2008.

Please continue reading further because the list goes on and some people jumped back in the line to ask questions. These are brief summary comments rom the Q&A session and some of the answers and questions were only able to be partially caught:


Continue article at 247WallSt.com



RELATED READING:
- Dendreon Gets Complete Response Letter
- Dendreon Nailed by FDA
- Dendreon Option Premiums Remain Astronomical

____________________